Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal

NOVEMBER 2, 2017

Radiopharmaceuticals expertise in Pharmatest

Pharmatest Services has successfully worked with radioactive compounds for almost a decade. Recent scientific publication in collaboration with Bayer shows an example of the strong expertise of Pharmatest in testing efficacy of radiopharmaceuticals in preclinical oncology models.

Pharmatest Services (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. In oncology Pharmatest has strong expertise in bone metastasis models.

Pharmatest has almost a decade of experience in testing efficacy of radioactive compounds in preclinical efficacy models. The studies have provided a large amount of scientific publications, including published papers in scientific journals, oral presentations and posters in leading scientific events.

The latest scientific paper was published in collaboration with Bayer in August 2017 in Clinical Cancer Research, demonstrating efficacy of radium-223 dichloride (Xofigo) to inhibit prostate cancer growth in bone microenvironment. The study continues the long collaboration between Pharmatest and Bayer with radiopharmaceuticals. The efficacy of Xofigo has been confirmed in clinical studies and Xofigo is currently in use in castration-resistant prostate cancer patients with advanced bone metastatic disease.

Jussi Halleen, CEO of Pharmatest says: “I am proud of the strong expertise of Pharmatest for testing efficacy of radiopharmaceuticals in preclinical studies. Setting up the capacity, training the personnel and obtaining the required licenses in compliance with relevant legislation has required lots of efforts over the years, and we can firmly state to be among the global leaders in the field.”